Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sanjay Mohan
- Target Recruit Count
- 51
- Registration Number
- NCT05799079
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis with Decitabine Combined with Filgrastim for Children and Young Adults with AML, MDS and Related Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Franziska Wachter
- Target Recruit Count
- 37
- Registration Number
- NCT05796570
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 98
- Registration Number
- NCT05766514
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentAcute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Registration Number
- NCT05740449
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-06-09
- Target Recruit Count
- 100
- Registration Number
- NCT05669079
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05586074
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 6
- Registration Number
- NCT05564650
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Jacqueline Garcia, MD
- Target Recruit Count
- 16
- Registration Number
- NCT05455294
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Huihan Wang
- Target Recruit Count
- 130
- Registration Number
- NCT05382390
- Locations
- 🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Genotype-guided Treatment in DLBCL
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT05351346
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.